On Thursday, September 13, 2018, at 12:00-1:00 p.m. EST, FDA Research Pharmacologist K. Barry Delclos, Ph.D. will present a Grand Rounds webinar on its BPA studies. The webinar will include information on the purpose of the BPA research program conducted by FDA and the NIEHS/NTP; the results of BPA pharmacokinetic studies and how these are combined with human exposure data in physiologically based pharmacokinetic models to predict internal exposures to BPA in humans exposed through food contact materials; and the results of BPA rat toxicology studies conducted over a broad dose range and how all of these data can contribute to assessing BPA safety in humans.
Bisphenol A, better known as BPA, is an industrial chemical used in producing polycarbonate plastics and epoxy resins used in consumer products like storage containers for foods and beverages, medical devices, and thermal paper. Consumers are mainly exposed to BPA through food containers and there has been much controversy as to the potential toxicity of this BPA exposure.
FDA’s National Center for Toxicological Research and the National Institute of Environmental Health Sciences (NIEHS)/National Toxicology Program (NTP) have conducted a series of studies in the past decade to address data gaps identified by the FDA Science Board and NTP.
Results of the NCTR toxicity studies indicated that BPA produced adverse effects at high doses, but not at the low end of the dose range tested, consistent with its activity as a weak estrogen. These results will inform ongoing BPA safety assessments, a topic of considerable public interest.
Attendees can receive CE credit for participation. To register and get more information on CE credit, visit FDA’s Grand Rounds webinar page.